PUBLIC COMPANY
save$BLCOBausch & Lomb Corp
$BLCO17.20-1.43%Vaughan, Ontario, CAupdated 5h ago
Bausch & Lomb is a Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.
community read0 votes
🐶 often sniffed alongside
top 3pipeline
17
marketed
16
phase 3
0
catalysts ytd
6
approvals ytd
3
recalls ytd
0
Pipeline(17)
view full pipeline →pipeline depth17 products
16Marketed1Unknown
Marketed
(bacitracin + hydrocortisone + neomycin sulfate + polymyxin B)
Anterior Segment Inflammation
Marketed(bacitracin + polymyxin B)
Bacterial Blepharoconjunctivitis
Marketed(dexamethasone + neomycin sulfate + polymyxin B)
Bacterial Conjunctivitis
MarketedLotemax SM
Ocular Pain (Eye Pain)
MarketedLumify
Ocular Inflammation
MarketedRetisert
Non-infectious Uveitis
MarketedTimoptic
Ocular Hypertension
MarketedZylet
Bacterial Conjunctivitis
Marketedacetylcholine chloride
Miosis
Marketedbepotastine besylate
Allergic Conjunctivitis
Marketedbesifloxacin hydrochloride
Bacterial Conjunctivitis
Marketedflurbiprofen sodium
Intraoperative Miosis
Upcoming
Recent(90d)
view all catalysts →Active trials
- phase2Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
- phase2A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
- phase4A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy
- N/AA Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract Extraction
- phase2A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy
- N/AA Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism
- phase1A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
- N/ASafety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 6, 26BUYSAUNDERS BRENT L· CEO and Chairman of the Board$252K↗
- Mar 6, 26BUYBailey A Robert D· EVP & Chief Legal Officer$250K↗
- Mar 6, 26BUYEldessouky Sam· EVP and CFO$69K↗
- Mar 3, 26BUYRoss Thomas W. Sr.· director$80K↗
- Mar 2, 26BUYAlfonso Eduardo· director$77K↗
- Feb 27, 26BUYVON ESCHENBACH ANDREW C.· director$80K↗
- Feb 23, 26BUYCOLLIS STEVEN H· director$267K↗
routine RSU / option mechanics (6)
- Mar 6, 26grantSAUNDERS BRENT L · CEO and Chairman of the Board14,700 sh
- Mar 6, 26grantEldessouky Sam · EVP and CFO4,000 sh
- Mar 6, 26grantBailey A Robert D · EVP & Chief Legal Officer14,600 sh
- Mar 3, 26grantRoss Thomas W. Sr. · director4,500 sh
- Mar 2, 26grantAlfonso Eduardo · director4,300 sh
- Feb 27, 26tax coverEldessouky Sam · EVP and CFO51,470 sh
🐶 Hiring Signal
next earnings Oct 28, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that